Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing OraSure Technologies’ regulatory paperwork can feel like sifting through lab samples—essential details are spread across hundreds of pages and dense FDA terminology. Whether you’re hunting for diagnostic-segment margins or tracking when executives trade shares, the disclosures are easy to miss. This page gathers every document the moment it hits EDGAR, delivering OraSure Technologies SEC filings explained simply.
Our AI engine reads the filings side-by-side with you, turning a 250-page OraSure Technologies annual report 10-K simplified into a two-minute brief, flagging revenue shifts driven by oral-fluid HIV tests and molecular collection kits. Need the next OraSure Technologies quarterly earnings report 10-Q filing? It appears here with instant OraSure Technologies earnings report filing analysis, plus red-lined changes from prior quarters. Real-time alerts highlight OraSure Technologies insider trading Form 4 transactions, so you can see OraSure Technologies Form 4 insider transactions real-time without refreshing the page.
Use the menu to jump straight to OraSure Technologies 8-K material events explained, the latest OraSure Technologies proxy statement executive compensation tables, or in-depth notes on FDA clearances embedded in footnotes. Our AI summaries clarify why a supply-chain disclosure matters, and a comparison tool helps professionals understand molecular solutions revenue trends quarter over quarter. Still unsure? A one-click guide for understanding OraSure Technologies SEC documents with AI answers common questions and points you to OraSure Technologies executive stock transactions Form 4 for context. Spend less time reading, more time deciding.
Earnest Partners, LLC filed Amendment No. 1 to a Schedule 13G reporting its holdings of OraSure Technologies, Inc. (OSUR) common stock. The amendment states Earnest Partners beneficially owned 795 shares, representing 0.0% of the class, and that it ceased to own more than 5% of the issuer as of December 31, 2022. The filing notes it was submitted late due to an inadvertent oversight and affirms the shares were not held with any control intent. The amendment is signed by the firm’s Chief Compliance Officer on 09/03/2025.
OraSure Technologies Chief Financial Officer Kenneth J. McGrath reported a Form 4 disclosing a tax-withholding disposition tied to the vesting of restricted stock. On 08/08/2025 the filing shows 12,524 shares were withheld to satisfy tax obligations at a reported price of $2.78 per share. After the withholding he beneficially owned 448,463 shares directly.
The filing is a routine Section 16 disclosure related to compensation vesting rather than an open-market sale. The explanation on the form explicitly states the shares were withheld to pay the tax liability associated with vested restricted shares, indicating this transaction reflects tax withholding on compensation.
OraSure Technologies (OSUR) – Form 4 filing, 07/31/2025: Director Robert W. McMahon satisfied tax withholding on recently vested restricted stock by having 7,317 common shares withheld by the company at an implied price of $3.205 per share (Transaction Code F). Following the transaction, McMahon continues to hold 99,919 shares directly. No derivative securities were reported.
Code F denotes a non-open-market disposition strictly for tax obligations; therefore, it does not represent an active sale decision and has minimal signalling value. The remaining stake indicates continued alignment with shareholders. No other transactions, options, or changes in beneficial ownership were disclosed.
FAQ
What is the current stock price of Orasure Tech (OSUR)?
What is the market cap of Orasure Tech (OSUR)?
